Back to top
more

Novartis (NVS)

(Delayed Data from NYSE)

$106.45 USD

106.45
1,174,113

-0.63 (-0.59%)

Updated Nov 8, 2024 04:00 PM ET

After-Market: $107.09 +0.64 (0.60%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 23% (57 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Glaxo (GSK) Q3 Earnings: Will it Deliver a Beat Yet Again?

by Zacks Equity Research

The performance of GlaxoSmithKline plc's (GSK) new products is likely to be good. Vaccines acquired from Novartis are likely to drive revenues and ease the impact of the loss of key drug, Advair .

    What's in the Cards for Amgen (AMGN) this Earnings Season?

    by Zacks Equity Research

    While Amgen's (AMGN) growth drugs like Prolia & Xgeva might continue to do well, biosimilar competition and slowdown in sales of mature products can put pressure on sales growth.

      Conatus' Liver Disease Drug Gets Orphan Drug Tag in the EU

      by Zacks Equity Research

      Conatus (CNAT) secures orphan drug designation for its pipeline candidate, IDN-7314, granted by the EMA. The candidate currently undergoes a phase II study on curing primary sclerosing cholangitis.

        Can ImmunoGen's Key Pipeline Cancer Candidate Drive Growth?

        by Zacks Equity Research

        Though ImmunoGen (IMGN) is progressing with lead ovarian cancer candidate, mirvetuximab soravtansine, the company is likely to face stiff market competition from established products upon approval.

          Conatus Entrusts Keith W. Marshall With Key Management Roles

          by Zacks Equity Research

          Conatus Pharmaceuticals (CNAT) announced the appointment of Keith W. Marshall as executive vice president, chief operating officer and chief financial officer.

            Teva Submits BLA to FDA for Migraine Candidate Fremanezumab

            by Zacks Equity Research

            Teva Pharma (TEVA) submits BLA seeking approval for its pipeline candidate, Fremanezumab, as a preventive treatment for migraine in the United States.

              Novartis Reports Positive Results on Thrombocytopenia Drug

              by Zacks Equity Research

              Novartis AG (NVS) announced encouraging results on Revolade from the EXTEND study.

                What's in the Cards for Novartis (NVS) This Earnings Season?

                by Zacks Equity Research

                Swiss pharmaceutical company Novartis AG (NVS) is scheduled to report third-quarter 2017 results on Oct 24.

                  Aerie (AERI) Up on FDA Review Committee Result for Rhopressa

                  by Zacks Equity Research

                  Shares of Aerie Pharmaceuticals, Inc. (AERI) have moved up 15.8% in the last week on positive news for its lead drug, Rhopressa.

                    Arpita Dutt headshot

                    Innovative Pipelines & Regulatory Catalysts to Drive Pharma Stocks

                    by Arpita Dutt

                    Innovation, mergers and acquisitions (M&As), strong results, product approvals and positive data flow should act as catalysts for pharma and biotech stocks.

                      Bristol-Myers (BMY), TARGET Extend Partnership for NASH Study

                      by Zacks Equity Research

                      Bristol-Myers Squibb (BMY) extended its strategic partnership with TARGET PharmaSolutions, Inc. for NASH study.

                        Lilly's Verzenio Gets Priority Review in First-Line Setting

                        by Zacks Equity Research

                        Eli Lilly and Company (LLY) announced that the FDA has granted priority review to its new drug application for Verzenio (abemaciclib) for the first-line treatment of advanced breast cancer.

                          Non-Alcoholic Steatohepatitis 2017 Progress Update

                          by Zacks Equity Research

                          Bigwigs of late have been investing a substantial portion of their R&D sources for the treatment of Non-Alcoholic Steatohepatitis (NASH).

                            Lilly's (LLY) Verzenio Fails in Phase III Lung Cancer Study

                            by Zacks Equity Research

                            Lilly's breast cancer drug, Verzenio, failed to achieve primary endpoint in a phase III study evaluating the drug as monotherapy in advanced lung cancer patients.

                              Arpita Dutt headshot

                              5 Pharma & Biotech Stocks That Could Be Big Winners in Q3 Earnings

                              by Arpita Dutt

                              Here is a look at 5 pharma and biotech stocks including Pfizer (PFE) that are expected to post a positive earnings surprise in Q3.

                                Roche (RHHBY) Receives FDA Approval For Cobas Zika Test

                                by Zacks Equity Research

                                The approval of cobas Zika will expands Roche's industry-leading donor screening portfolio for blood-borne diseases.

                                  Lilly Wins Favorable Ruling From U.S. PTO in Alimta Dispute

                                  by Zacks Equity Research

                                  Lilly (LLY) has received a favorable ruling from the U.S. PTO in a dispute related to vitamin regimen patent on its key cancer drug, Alimta.

                                    Teva Down as Mylan's Copaxone 40 mg Generic Arrives Early

                                    by Zacks Equity Research

                                    Teva's (TEVA) shares plunged after Mylan announced an earlier-than-expected launch of its generic version of the 40-mg thrice-weekly formulation of its blockbuster multiple sclerosis drug, Copaxone.

                                      FDA Accepts Roche's (RHHBY) Application for Adjuvant Perjeta

                                      by Zacks Equity Research

                                      Roche Holdings AG (RHHBY) announced that the FDA has accepted the company's sBLA and granted Priority Review for breast cancer drug regimen Perjeta

                                        Ryan McQueeney headshot

                                        Here's Why Bluebird Bio (BLUE) Stock Is Falling Today

                                        by Ryan McQueeney

                                        Shares of Bluebird Bio (BLUE), a major player in the emerging gene therapy and CAR-T research markets, slumped more than 6% in morning trading Monday after receiving a key analyst downgrade.

                                          Ligand's Captisol Deals Set to Drive Growth in the Long Run

                                          by Zacks Equity Research

                                          Ligand's (LGND) Captisol formulation technology platform allows it to partner with several leading drug companies, thus helping it earn milestones and royalty payments in turn.

                                            Teva Reintroduces Generic Depo-Provera Injection in U.S.

                                            by Zacks Equity Research

                                            Teva (TEVA) announced the reintroduction of the generic equivalent to Depo-Prover Contraceptive Injection 150 mg/mL in the United States.

                                              Intercept (ICPT) Provides Safety Guidelines For Ocaliva

                                              by Zacks Equity Research

                                              Intercept Pharmaceuticals, Inc. (ICPT) provided a statement on the recent safety and dosing issues for lead drug Ocaliva and reinforced that the recommended dosing is safe.

                                                AstraZeneca's Bevespi Improves Lung Function in Phase III Study

                                                by Zacks Equity Research

                                                AstraZeneca plc (AZN) announced top-line data from a late stage study, which showed that its Bevespi Aerosphere led to a statistically significant improvement in lung function in patients with COPD.

                                                  Arpita Dutt headshot

                                                  3 Heart Disease Focused Stocks to Buy Ahead of World Heart Day

                                                  by Arpita Dutt

                                                  With World Heart Day coming up, here is a look at some well-positioned stocks including BioTelemetry (BEAT) in this segment of the market.